- Home
- SCNI vs GLMD Comparison
SCNI vs GLMD Comparison
Compare SCNI & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNI
- GLMD
- Stock Information
- Founded
- SCNI 2003
- GLMD 2000
- Country
- SCNI Israel
- GLMD Israel
- Employees
- SCNI N/A
- GLMD N/A
- Industry
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- SCNI Health Care
- GLMD Health Care
- Exchange
- SCNI Nasdaq
- GLMD Nasdaq
- Market Cap
- SCNI 3.5M
- GLMD 5.9M
- IPO Year
- SCNI N/A
- GLMD 2014
- Fundamental
- Price
- SCNI $3.65
- GLMD $3.46
- Analyst Decision
- SCNI
- GLMD
- Analyst Count
- SCNI 0
- GLMD 0
- Target Price
- SCNI N/A
- GLMD N/A
- AVG Volume (30 Days)
- SCNI 31.9K
- GLMD 1.1M
- Earning Date
- SCNI 10-29-2024
- GLMD 11-20-2024
- Dividend Yield
- SCNI N/A
- GLMD N/A
- EPS Growth
- SCNI N/A
- GLMD N/A
- EPS
- SCNI N/A
- GLMD N/A
- Revenue
- SCNI $284,000.00
- GLMD N/A
- Revenue This Year
- SCNI N/A
- GLMD N/A
- Revenue Next Year
- SCNI N/A
- GLMD N/A
- P/E Ratio
- SCNI N/A
- GLMD N/A
- Revenue Growth
- SCNI N/A
- GLMD N/A
- 52 Week Low
- SCNI $2.23
- GLMD $2.73
- 52 Week High
- SCNI $8.92
- GLMD $23.80
- Technical
- Relative Strength Index (RSI)
- SCNI 48.94
- GLMD 41.41
- Support Level
- SCNI $3.52
- GLMD $3.60
- Resistance Level
- SCNI $3.94
- GLMD $4.15
- Average True Range (ATR)
- SCNI 0.27
- GLMD 0.56
- MACD
- SCNI 0.00
- GLMD -0.28
- Stochastic Oscillator
- SCNI 52.31
- GLMD 1.46
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.